Skip to main content

Advertisement

SpringerLink
Log in

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor

  • Introduction to Review Articles
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer (translated from Eng). J Clin Oncol 14(8):2197–2205 (in Eng)

    CAS  PubMed  Google Scholar 

  2. Rahman ZU, Frye DK, Smith TL et al (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference (translated from Eng). Cancer 85(1):104–111 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  3. Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies (translated from Eng). Cancer 104(8):1742–1750 (in Eng)

    Article  PubMed  Google Scholar 

  4. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? (translated from Eng). Cancer 100(1):44–52 (in Eng)

    Article  PubMed  Google Scholar 

  5. Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (translated from Eng). J Clin Oncol 16(10):3439–3460 (in Eng)

    CAS  PubMed  Google Scholar 

  6. Gralow JR (2005) Optimizing the treatment of metastatic breast cancer (translated from Eng). Breast Cancer Res Treat 89(Suppl 1):S9–S15 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  7. Tot T, Tabar L (2011) The role of radiological–pathological correlation in diagnosing early breast cancer: the pathologist’s perspective (translated from Eng). Virchows Arch 458(2):125–131 (in Eng)

    Article  PubMed  Google Scholar 

  8. Lianidou ES, Mavroudis D, Georgoulias V (2013) Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer (translated from Eng). Br J Cancer 108(12):2426–2432 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Rothe F, Laes JF, Lambrechts D et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer (translated from Eng). Ann Oncol 25(10):1959–1965 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  10. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer (translated from Eng). J Clin Oncol 16(7):2401–2408 (in Eng)

    CAS  PubMed  Google Scholar 

  11. Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer (translated from Eng). Breast Cancer 15(4):278–290 (in Eng)

    Article  PubMed  Google Scholar 

  12. Osborne CK (1998) Tamoxifen in the treatment of breast cancer (translated from Eng). N Engl J Med 339(22):1609–1618 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  13. Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial (translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  14. Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer (translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)

    Article  PubMed  Google Scholar 

  15. Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian–New Zealand Breast Cancer Trials Group (translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)

    CAS  PubMed  Google Scholar 

  16. Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease (translated from Eng). Br Med J 2(4368):393–398 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study (translated from Eng). JAMA 302(7):774–780 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study (translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis (translated from Eng). Adv Ther 30(10):870–884 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Rocca A, Farolfi A, Bravaccini S et al (2014) Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer (translated from Eng). Expert Opin Pharmacother 15(3):407–420 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  21. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer (translated from Eng). J Clin Oncol 26(12):1987–1992 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  22. Robertson JF, Howell A, Gorbunova VA et al (2005) Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant (translated from Eng). Breast Cancer Res Treat 92(2):169–174 (in Eng)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The author and his immediate family members declare their conflicts of interest as follows: employment, not applicable (N/A); leadership, N/A; consultant, N/A; stock, N/A; honoraria, AstraZeneca; research funds, Chugai-Roche, AstraZeneca, Novartis, Takeda, Taiho; testimony, N/A; other, N/A.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Surgery, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan

    Hirotaka Iwase

Authors
  1. Hirotaka Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotaka Iwase.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwase, H. Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol 20, 249–252 (2015). https://doi.org/10.1007/s10147-015-0795-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0795-6

Keywords

Search

Navigation